BACKGROUND: Since 2006 Human papillomavirus (HPV) vaccination has become
available to adolescent girls and women in an increasing number of countries, to protect …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …

Background Mortality rates from cervical cancer demonstrate deep inequality in health
between richer and poorer populations. Over 310 000 women died of this preventable …

Human papilloma virus (HPV) vaccination has been implemented in several countries for
about the past 7 years, mainly in the adolescent female population, with varying coverage …

Background HPV is related to a number of cancer types, causing a considerable burden in
both genders in Europe. Female vaccination programs can substantially reduce the …

Background HPV vaccine is a prophylactic vaccine to prevent HPV infections.
Recommended by the World Health Organization, this vaccine is clinically proven to be one …

Background: Adolescent HPV (Human Papilloma Virus) vaccination is yet to be introduced
as a mandatory program in Poland. Polish literature on factors associated with adolescent …

Cancer imposes a heavy societal burden worldwide, in terms of both epidemiology and
costs. The introduction of more sophisticated imaging and diagnostic techniques and …

Introduction Human papillomavirus (HPV) is the commonest sexually transmitted infection
worldwide and causes substantial morbidity in both sexes. Most European countries offer …

Background Cervical cancer is the leading cause of female cancer-related deaths in
Tanzania. Vaccination against human papillomavirus (HPV) offers a new opportunity to …